替格瑞洛-阿司匹林与氯吡格雷-阿司匹林在轻型卒中或短暂性脑缺血发作不同病因中的疗效与安全性:CHANCE-2试验预设分析
CHANCE-2试验预设分析纳入6336例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,按TOAST病因分型评估替格瑞洛-阿司匹林与氯吡格雷-阿司匹林的有效性和安全性。结果显示不同病因亚型中两种双联抗血小板治疗的疗效和安全性一致,治疗与病因亚型的交互作用无统计学意义(P=0.08)。
要点
- 小血管闭塞亚型中替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低新发卒中风险(HR 0.51,95%CI 0.33-0.79;P=0.002)。
- 大动脉粥样硬化型和病因不明型中新发卒中风险两组无显著差异。
- 不同病因亚型中严重或中度出血事件无显著差异。
核心结论
- 在CHANCE-2试验的预设分析中,替格瑞洛-阿司匹林与氯吡格雷-阿司匹林预防新发卒中的疗效和安全性在不同病因患者中一致。
- 卒中病因对基因导向抗血小板治疗获益的影响需进一步试验探索。
研究设计与样本
- CHANCE-2试验的预设分析,纳入6412例携带CYP2C19功能缺失等位基因的轻型卒中或短暂性脑缺血发作患者,其中6336例经集中评估TOAST分型(大动脉粥样硬化、小血管闭塞、病因不明)纳入本分析。
- 主要疗效结局为90天内新发卒中,主要安全结局为90天内严重或中度出血;采用Cox比例风险模型评估TOAST分型与替格瑞洛-阿司匹林对比氯吡格雷-阿司匹林疗效的交互作用。
主要发现
- 大动脉粥样硬化型患者中,替格瑞洛-阿司匹林组85例(9.8%)与氯吡格雷-阿司匹林组88例(10.7%)发生卒中复发(HR 0.86,95%CI 0.63-1.18;P=0.34)。
- 小血管闭塞型患者中,替格瑞洛-阿司匹林组32例(3.6%)与氯吡格雷-阿司匹林组61例(7.0%)发生卒中复发(HR 0.51,95%CI 0.33-0.79;P=0.002)。
- 病因不明型患者中,替格瑞洛-阿司匹林组68例(4.8%)与氯吡格雷-阿司匹林组87例(5.9%)发生卒中复发(HR 0.80,95%CI 0.58-1.10;P=0.17)。
- 治疗与病因亚型的交互作用P=0.08。
- 不同病因和不同治疗的患者中严重或中度出血事件无显著差异。
局限性
- 原文结论指出卒中病因对基因导向抗血小板治疗获益的影响需进一步试验探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether patients with different stroke/transient ischemic attack etiologies benefit differently from gene-directed dual antiplatelet therapy. This study explored the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in transient ischemic attack or minor stroke with different causes in the CHANCE-2 trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events-II). METHODS: This was a prespecified analysis of the CHANCE-2 trial, which enrolled 6412 patients with minor stroke or transient ischemic attack who carried CYP2C19 loss-of-function alleles. Patients with centralized evaluation of TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification of large-artery atherosclerosis, small-vessel occlusion, and stroke of undetermined cause were included. The primary efficacy outcome was new stroke, and the primary safety outcome was severe or moderate bleeding, both within 90 days. Cox proportional hazards models were used to assess the interaction of TOAST classification with the effects of dual antiplatelet therapy with ticagrelor-aspirin versus clopidogrel-aspirin. RESULTS: A total of 6336 patients were included in this study. In patients administered ticagrelor-aspirin and clopidogrel-aspirin, respectively, stroke recurred in 85 (9.8%) and 88 (10.7%) patients with large-artery atherosclerosis (hazard ratio, 0.86 [95% CI, 0.63-1.18]; P=0.34); 32 (3.6%) and 61 (7.0%) patients with small-vessel occlusion (hazard ratio, 0.51 [95% CI, 0.33-0.79]; P=0.002); and 68 (4.8%) and 87 (5.9%) patients with stroke of undetermined cause (hazard ratio, 0.80 [95% CI, 0.58-1.10]; P=0.17), with P=0.08 for the treatment×cause subtype interaction effect. There were no significant differences in severe or moderate bleeding events in patients with different cause and different treatment. CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04078737.
引用
- Xie X, Jing J, Meng X, et al. Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial. Stroke. 2023. PMID: 37548009. doi:10.1161/STROKEAHA.122.042233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。